Evidence map›Paper›PMID 28450959›Full record

ArticleExperimental and therapeutic medicine2017

Changes in liver stiffness and its associated factors during oral antiviral therapy in Chinese patients with chronic hepatitis B.

Xu Li, Qinglong Jin, Hong Zhang, Xue Jing, Zhongyang Ding, Hongjie Zhou, Zetian Zhang, Dongqing Yan, Dongmei Li, Pujun Gao and 1 more

Abstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xu LiDepartment of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Qinglong JinDepartment of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Hong ZhangPhase I Clinical Trials Unit, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Xue JingDepartment of Gastroenterology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong 266000, P.R. China.
Zhongyang DingDepartment of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Hongjie ZhouDepartment of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Zetian ZhangDepartment of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Dongqing YanDepartment of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Dongmei LiDepartment of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Pujun GaoDepartment of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.
Junqi NiuDepartment of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to assess improvements in liver stiffness determined by transient elastography and associated factors in Chinese patients with chronic hepatitis B (CHB) during long-term treatment with oral antiviral drugs. A total of 334 consecutive Chinese patients with CHB who underwent oral antiviral therapy and received at least two liver stiffness measurements (LSMs) at the First Hospital of Jilin University (Changchun, China) from December 2012 to February 2015 were enrolled in the present study. The cohort included 201 patients without liver cirrhosis (group 0) and 133 patients with liver cirrhosis (group 1). Each patient was subjected to LSM twice with an interval of 6 months. The mean initial liver stiffness values were 14.01±9.37 and 21.59±10.25 kPa for patients in group 0 and group 1, respectively (P<0.001). Multivariate analysis revealed that higher aspartate aminotransferase and lower alanine aminotransferase levels at baseline as well as higher α-fetoprotein levels at follow-up (24 weeks) were associated with a greater decline of liver stiffness in group 0. Furthermore, a higher liver stiffness at baseline and a longer course of antiviral therapy prior to the initial LSM were significantly correlated with a reduction of liver stiffness, whereas higher total bilirubin levels at follow-up contributed to increased liver stiffness in group 1. In conclusion, LSM at the beginning and the end of a 24-week observation period showed that antiviral drug therapy significantly improved in group 1, while a marked decreasing trend was also observed in group 0. In group 0, the reduction of liver stiffness was correlated with liver inflammation, whereas in group 1, it was correlated with the treatment duration prior to the initial LSM and serum levels of hepatitis B virus DNA. Furthermore, a higher liver stiffness at baseline was associated with a greater reduction of liver stiffness in each group.

Indexed as

anti-viral drugchronic hepatitis Bliver fibrosis

Identifiers

PMID28450959
PMCPMC5403208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.